EMI Share Option Scheme
Abingdon Health plc has allocated 3,096,000 share options under its EMI share option scheme to UK-based staff employed for at least 12 months, representing 1.23% of total issued shares. Half of these options, 1,548,000, will be allocated in April 2026, with the remaining 1,548,000 to be allocated in April 2027, and all shares will be exercisable at nil cost three years post-allocation.
Select text to share a quote on X · sign in to keep highlights & notes in your ABDX notes
York, U.K. 15 April 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that it has allocated a total of 3,096,000 shares options under its pre-existing EMI share option scheme to be provided to all UK based staff who have been employed by the company for 12 months or more.
Shares to a total of 1,548,000 shares will be allocated in April 2026 with an additional 1,548,000 to be allocated in April 2027. Shares will be exercisable at nil cost 3 years post allocation.
The total number of EMI option shares being allocated as described above is 3,096,000 shares or 1.23% of total issued shares.
| Abingdon Health plc | www.abingdonhealth.com/investors/ |
| Chris Hand, Executive Chairman | Via Walbrook PR |
| T om Hayes, CFO | |
| Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 7220 0500 |
Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance) Nigel Birks (Life Science Specialist Sales)
| Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.